A recent announcement from OncoGenex Pharmaceuticals Inc. declares the company executed an initial understanding with Teva Pharmaceutical Industries Ltd. to regain the rights for custirsen, the investigational compound that is currently undergoing a Phase 3 trial for ... Read more